Document is current

Article History

Received: 29 August 2025

Accepted: 21 November 2025

First Online: 7 January 2026

Declarations

:

: The CHRONICLE study was performed in accordance with ethical principles consistent with the Declaration of Helsinki, International Council for Harmonisation Good Clinical Practice guidelines, guidelines for Good Pharmacoepidemiology Practices, the Health Insurance Portability and Accountability Act, and applicable legislation for observational studies. The study protocol was approved by a central institutional review board (Advarra, Columbia, MD). All patients provided written informed consent at enrolment.

: Not applicable.

: RAP has served on advisory boards and received grant support from AstraZeneca, Genentech, Novartis, Regeneron Pharmaceuticals and Sanofi. AM has served on the advisory board for Regeneron Pharmaceuticals and Verona Pharmaceuticals. NLL has served as an advisor and consultant for AbbVie, Amgen, Apogee, AstraZeneca, Avillion, Foresee, Genentech, GSK, Niox, Novartis, Regeneron Pharmaceuticals, Sanofi, and Teva Pharmaceuticals; and has received grant support from Amgen, AstraZeneca, Avillion, Bellus, Evidera, Gossamer Bio, Genentech, GSK, Janssen, Novartis, Regeneron Pharmaceuticals, Roche, Sanofi, and Teva Pharmaceuticals. She is an honorary faculty member of the Observational and Pragmatic Research Institute but does not receive compensation for this role. DKL has received consulting fees from AstraZeneca and GSK; has received speaker fees from AstraZeneca, Genentech/Roche, GSK, and Sanofi/Regeneron Pharmaceuticals; and has received research support paid to the institution by AstraZeneca. DDC and CSA are employees of AstraZeneca and may own stock or stock options in AstraZeneca.